West Pharmaceutical Services, Inc. — Q2 2022 Form 10-Q Summary
Business context and reporting period
West designs and manufactures containment, packaging, drug-delivery and contract-manufactured products for biologic, generic, pharmaceutical, diagnostic and medical-device customers. The filing covers the three and six months ended June 30, 2022; financial statements are unaudited and prepared under U.S. GAAP.
The company reports two segments: Proprietary Products and Contract-Manufactured Products. Proprietary Products represented approximately 85% of second-quarter sales and Contract-Manufactured Products approximately 15%.
Key financial metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Net sales | $771.3 million, up 6.6% | $1,491.3 million, up 7.0% |
| Gross profit | $321.5 million | $606.1 million |
| Gross margin | 41.7%, down from 43.5% | 40.6%, down from 42.1% |
| Operating profit | $228.4 million, up 8.1% | $418.1 million, up 8.1% |
| Operating margin | 29.6%, up from 29.2% | 28.0%, up from 27.7% |
| Net income | $188.5 million, up 0.6% | $362.3 million, up 7.0% |
| Diluted EPS | $2.48, versus $2.47 | $4.77, versus $4.47 |
| Operating cash flow | Not separately provided | $324.3 million, versus $233.1 million |
Second-quarter sales growth reflected $71.7 million of volume and mix gains and $23.4 million of price increases, partly offset by a $47.4 million unfavorable currency effect. Organic sales growth was 13.1% for the quarter and 12.1% for the first half.
- Proprietary Products sales increased 11.3% reported and 18.3% organically in the quarter, driven primarily by high-value products including NovaPure.
- Contract-Manufactured Products sales declined 13.6% reported and 8.9% organically, primarily due to lower diagnostic-device component sales.
- Higher inflation-related labor, transportation and overhead costs reduced gross margins, particularly in Proprietary Products.
- SG&A declined 12.1% in the quarter and 4.6% year to date, primarily due to lower incentive compensation, currency effects and allocation of functional costs to cost of goods sold.
Liquidity, debt and capital allocation
- Cash and cash equivalents were $718.5 million at June 30, 2022, compared with $762.6 million at December 31, 2021.
- Working capital was $1,206.0 million, compared with $1,147.9 million at year-end.
- Total debt was $252.0 million, including $44.2 million classified as current and $207.8 million of long-term debt. The remaining $42.0 million Series A notes were repaid on July 5, 2022.
- The revolving credit facility was increased from $300 million to $500 million and extended to March 2027. Available capacity, including outstanding letters of credit, was $497.6 million; there were no borrowings under the facility.
- The company was in compliance with all debt covenants at June 30, 2022.
- First-half capital expenditures were $131.9 million, compared with $111.6 million in the prior-year period.
- First-half share repurchases totaled $175.7 million for 476,667 shares, and dividends paid totaled $26.5 million.
Material changes versus the prior comparable period
- Revenue and operating profit increased, but currency translation materially reduced reported growth.
- Gross margin declined 180 basis points in the quarter and 150 basis points year to date because of inflation, higher plant spending and overhead costs.
- Net income growth was limited in the quarter by a higher effective tax rate of 19.5%, compared with 15.3% in the prior-year quarter. The year-to-date effective tax rate was unchanged at 15.8%.
- Operating cash flow improved by $91.2 million year to date, while investing cash use increased by $23.9 million and financing cash use increased by $52.8 million, primarily because of higher share repurchases.
- Accumulated other comprehensive loss increased to $245.9 million from $159.6 million, primarily because of $86.5 million of adverse foreign-currency translation adjustments.
- Other income included a $1.6 million restructuring benefit in the quarter and $3.1 million of oil-hedge gains year to date. These items are not necessarily indicative of recurring operations.
Outlook, commentary, risks and unusual items
Management stated that liquidity and capital resources remain strong and expects cash on hand, operating cash flow and available revolving-credit capacity to meet foreseeable liquidity needs. The filing does not provide a clear quantitative full-year revenue or earnings guidance figure.
- COVID-19 had limited operational impact through the period, but future effects remain uncertain, including employee health, supplier continuity, transportation and customer demand.
- The Russia-Ukraine war had not materially affected results through June 30, 2022, although management was monitoring raw-material availability, logistics and European energy costs.
- Key risks include supply-chain interruptions, inflation and petroleum-based raw-material costs, labor availability, pricing execution, customer inventory changes, product and regulatory approval timing, competition, foreign-exchange volatility and reliance on third-party suppliers, including Daikyo.
- The company uses foreign-exchange, interest-rate and crude-oil derivatives to manage exposures; outstanding crude-oil options covered 257,999 barrels at a weighted-average strike price of $107.02 per barrel.
- There were no material changes to previously disclosed commitments, contingencies or risk factors, and no material off-balance-sheet financing arrangements beyond ordinary-course purchase obligations and letters of credit.
- Management reported effective disclosure controls and no material changes to internal control over financial reporting. No legal proceedings were reported.
Important facts for investors to verify
- Whether Proprietary Products growth and high-value product demand can offset continued weakness in Contract-Manufactured Products.
- Whether price increases and productivity improvements can offset inflation, labor, transportation and raw-material costs and restore gross margins.
- The effect of foreign-exchange movements, particularly the stronger U.S. dollar, on reported sales, profit and accumulated other comprehensive loss.
- The pace and return on elevated capital expenditures and the company’s ability to fund them while continuing share repurchases and dividends.
- The July 5, 2022 repayment of the $42.0 million Series A notes and subsequent debt and liquidity levels.
- Whether COVID-19, geopolitical developments and supply-chain constraints create material changes after the reporting date.